MP
CTOR

Mangrove Partners’s Citius Oncology CTOR Stock Holding History

Mangrove Partners’s Portfolio CTOR Stock Details CTOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-150,000
Closed -$1.52M – 278
2022
Q4 		$1.52M Buy
+150,000
New +$1.52M 0.09% 230

Other funds holding CTOR

WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
KIM
Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return

Mangrove Partners's CTOR Position: Q1 2023 in Review

Mangrove Partners sold out of Citius Oncology (CTOR) in Q1 2023, closing a stake of 150,000 shares — an estimated $1.52M sold.

Mangrove Partners first reported a position in CTOR in Q4 2022 and held it in 1 quarter. The position peaked at $1.52M in Q4 2022. 24 funds tracked by Wall St. Rank hold CTOR as of Q1 2023.

  • Mangrove Partners reported no remaining Citius Oncology position as of Q1 2023 after selling out during the quarter.
  • Mangrove Partners sold 150,000 Citius Oncology shares in Q1 2023, an estimated $1.52M.
  • Mangrove Partners first reported a position in Citius Oncology in Q4 2022 and held it in 1 quarter.
  • Mangrove Partners's Citius Oncology position peaked at $1.52M in Q4 2022.
  • 24 funds tracked by Wall St. Rank held Citius Oncology as of Q1 2023.

Based on Mangrove Partners's 13F filing for Q1 2023, filed 15 May 2023.